In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

"It's pretty well known in the field that the androgen receptor gets hijacked in a variety of ways and starts taking on new functions to drive prostate cancer cell growth," said senior author Dr ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

The incidence of prostate cancer continues to increase in the ... 38 The action of androgens within prostate cells is mediated by androgen-receptor proteins, which bind to DNA to activate ...

The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to the Vanderbilt University Medical Center study ...

The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to a new study.

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

Over the past 14 years, clinicians have seen rapid growth in their therapeutic armamentarium to treat advanced prostate cancer ... hormone therapies (the androgen receptor pathway inhibitors ...

His research covers everything from inherited mutations that increase the risk of developing advanced prostate cancer to the link between aging ... the role of the androgen receptor pathway and the ...